CAR T‑Cell Cardiac Eligibility & Cardiotoxicity Findings

UnitedHealthcare’s March 2026 CAR T‑cell guideline update emphasizes cardiac eligibility criteria and observed cardiotoxicity in clinical trials and real‑world cohorts. Trials used varying LVEF exclusion thresholds (Yescarta <50%, Kymriah <45%, Breyanzi cohorts with <40–50% exclusions), underscoring heterogeneity in cardiac selection. A retrospective cohort (Alvi et al., 2019) found 12% cardiac event rate, troponin elevations common, and all events occurred with grade ≥2 CRS; each 12‑hour delay to tocilizumab was linked to a 1.7‑fold higher cardiovascular risk. The guideline notes evidence gaps around routine troponin monitoring and whether earlier CRS intervention reduces cardiac events.

This revision summarizes UnitedHealthcare's Clinical Guidelines text for CAR T‑cell therapies (effective 2026-03-11) with specific attention to cardiac and cardiovascular considerations present in the cited clinical trials and observational studies. The document compiles eligibility criteria and safety findings from pivotal trials and cohort analyses for commercially available CAR T products including axicabtagene ciloleucel (Yescarta®), tisagenlecleucel (Kymriah®), and lisocabtagene maraleucel (Breyanzi®). The revision highlights trial exclusion thresholds for cardiac function (left ventricular ejection fraction), reported cardiac event rates in observational data, and how cardiovascular events related to cytokine release syndrome (CRS) were temporally associated with troponin elevation and tocilizumab administration.

The source text integrates both product-specific trial eligibility/exclusion data (e.g., LVEF cutoffs) and a retrospective study (Alvi et al., 2019) that quantified cardiac adverse events and their relationship to CRS severity and treatment timing. No new coverage decisions, CPT codes, or policy numbers are introduced in the provided excerpt; the focus is on clinical eligibility and observed cardiovascular risks in CAR T therapy populations.

The guideline text consolidates universal minimum eligibility requirements referenced from ASTCT expert opinion (Jain et al., 2019). Cardiac evaluation is explicitly listed as a required element of eligibility assessment, with LVEF (left ventricular ejection fraction) noted among other organ-function parameters (renal, hepatic, pulmonary, hematologic, neurologic). Baseline assessment also includes evaluation of comorbidities such as autoimmune disease, use of immunosuppressive agents, and active or uncontrolled infection—factors that could indirectly affect cardiovascular risk during CAR T therapy.

The document includes safety data highlighting cardiovascular adverse events associated with CAR T therapies. In the Alvi et al. (2019) retrospective cohort of 137 patients, cardiac events occurred in 17 patients (12%), which included 6 cardiovascular deaths, 6 episodes of decompensated heart failure, and 5 arrhythmias. Troponin elevation was common among the subset evaluated (29 of 53; 54%), and declines in LVEF were observed in 8 of 29 patients (28%). Importantly, all cardiac events occurred in the setting of grade 2 or greater CRS, and 95% followed troponin elevation.

This safety signal links myocardial injury markers and subsequent cardiac decompensation to the systemic inflammatory response of CRS. The text also reports that the timing of tocilizumab administration was associated with cardiovascular outcomes: each 12‑hour delay from CRS onset to tocilizumab was associated with a 1.7‑fold increase in risk of cardiovascular events in that cohort.

Product-specific trial populations and exclusion criteria relevant to cardiovascular risk are summarized in the guideline text. For axicabtagene ciloleucel (Yescarta®), ZUMA‑1 excluded patients with cardiac ejection fraction < 50% and those with active serious infection; lymphodepletion consisted of fludarabine and cyclophosphamide followed by a target CAR T dose of 2 x 10^6 CAR‑positive viable T cells/kg. For tisagenlecleucel (Kymriah®), JULIET excluded patients with ejection fraction < 45% and reported CRS in 58% of patients with median onset 3 days and median duration 7 days; responses were managed with tocilizumab and glucocorticoids.

Lisocabtagene maraleucel (Breyanzi®) study cohorts included patients with reduced organ reserve (e.g., LVEF < 50% allowed in the PILOT transplant‑ineligible cohort) but other trials excluded LVEF < 40%. The Breyanzi trials permitted bridging therapy in many patients and reported efficacy metrics (e.g., objective response rates) but also employed LVEF‑based exclusions in certain cohorts, demonstrating heterogeneity in cardiac eligibility across clinical development programs.

The policy text highlights areas identified by investigators as needing further study related to cardiovascular monitoring and management. The Alvi et al. cohort discusses the potential utility of routine troponin measurement to detect myocardial injury and suggests that earlier intervention for CRS (potentially guided by troponin) might mitigate cardiovascular events. The document notes that additional studies are warranted to define the clinical utility of troponin monitoring, evaluate earlier intervention thresholds for less severe CRS, and test whether tocilizumab administration based on troponin values improves outcomes.

These observations reflect an evidence gap: existing trial exclusion criteria used LVEF thresholds to select lower cardiac‑risk populations, while retrospective data indicate clinically significant cardiovascular events in real‑world CAR T recipients, particularly in the context of CRS and delayed anti‑IL‑6 therapy.

OpenPayer

March 2026 Revision: Emphasis on Cardiac Eligibility and Cardiotoxicity Findings

Eligibility Requirements: Baseline Cardiac Function and Organ Assessment

Observed Cardiac Adverse Events and Association with Cytokine Release Syndrome

Trial Enrollment, Lymphodepletion, and LVEF-Based Exclusions Across CAR T Products

Identified Evidence Gaps: Troponin Monitoring and Timing of CRS Intervention